Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bushen Fangchuan Pian is a traditional Chinese medicine (TCM) compound formula, typically used in China for the management of chronic respiratory diseases. The name translates to "Kidney-Tonifying and Asthma-Preventing Tablet." It is formulated based on TCM principles that associate kidney deficiency with chronic respiratory symptoms such as asthma or chronic obstructive pulmonary disease (COPD). The formula generally contains a combination of herbal ingredients designed to tonify the kidney, support qi (vital energy), and relieve symptoms like wheezing and shortness of breath. Its mechanism is rooted in TCM theory rather than modern pharmacology; it aims to restore balance by nourishing kidney function and supporting lung health. Clinical studies registered in China have evaluated its use as an adjunct therapy for patients with chronic airway diseases, but robust evidence from large-scale randomized controlled trials remains limited.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bushen Fangchuan Pian.